Tetra Bio-Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TBPMF research report →
Price Chart
About the company
Tetra Bio-Pharma Inc. (TBPMF) is a biopharmaceutical company dedicated to discovering and advancing cannabinoid-based medications. Its research and development efforts span crucial medical fields, including inflammation, pain management, ophthalmology, and oncology.
- CEO
- Guy Chamberland Master Herbal
- IPO
- 2012
- Employees
- 33
- HQ
- Orléans, ON, CA
Get TickerSpark's AI analysis on TBPMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.87M
- P/E
- -0.21
- PEG
- 0.66
- P/S
- 0.00
- P/B
- 44.69
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -467.81%
- ROIC
- -739.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-24,841,290
- Net Income
- $-52,175,046-97.1%
- EPS
- $-0.12-20.0%
- OCF Growth
- -28.7%
- FCF Growth
- -21.3%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.98
- RSI (14)
- 50
- Avg Volume
- 365.00K
No earnings-call transcripts are available for TBPMF yet.
- Free Float
- 4.8%
- Shares Outstanding
- 8.75B
- Float Shares
- 418.75M
Our TBPMF coverage
Recent articles, reports, and earnings notes.
No research on TBPMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TBPMF report →Tetra Bio-Pharma & Avicanna Enter Into Strategic Partnership
benzinga.com · Feb 14
Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials Of QIXLEEF For Cancer Pain
benzinga.com · Nov 29
Tetra Bio-Pharma advancing breakthrough pain drug QIXLEEF to late clinical development stage
proactiveinvestors.com · Oct 14
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
prnewswire.com · Oct 14
Tetra Bio-Pharma says its first cannabinoid-derived medicine REDUVO is a ‘major milestone' as it gears up to launch it
proactiveinvestors.com · Oct 5
Tetra Bio-Pharma draws positive Scientific Advice Assessment report for its cannabinoid-based drug candidate QIXLEEF
proactiveinvestors.com · Sep 2
Tetra Bio-Pharma receives positive Scientific Advice Assessment report for its cannabinoid-based drug candidate QIXLEEF
proactiveinvestors.com · Sep 2
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
prnewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.